EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study

Authors
Category Primary study
JournalJournal of Hepatology
Year 2020
This article has no abstract
Epistemonikos ID: bf7ec63e14654c279a0d11b6c875fa84d9b72d9f
First added on: Feb 12, 2025